6533b82cfe1ef96bd128f7b5
RESEARCH PRODUCT
Oxidative stress in patients with Alzheimer's disease: Effect of extracts of fermented papaya powder
Mario BarbagalloFrancesco MarottaLigia J. Dominguezsubject
MaleAntioxidantSettore MED/09 - Medicina Internamedicine.medical_treatmentReview Articlemedicine.disease_causeAntioxidantsLipid peroxidationchemistry.chemical_compoundchemistry.chemical_classificationAged 80 and overbiologyCaricaBrainBiochemistry8-Hydroxy-2'-DeoxyguanosineFemalePowdersCaricaAlzheimer's diseaseAntioxidantCase-Control StudieReactive Oxygen SpecieOxidation-Reductionlcsh:RB1-214Humanmedicine.medical_specialtyUrinary systemImmunologyPowderAlzheimer DiseaseInternal medicinemedicinelcsh:PathologyHumansAgedDietary SupplementReactive oxygen speciesCase-control studyDeoxyguanosineOxidative StrePlant PreparationCell Biologybiology.organism_classificationmedicine.diseaseAged; Aged 80 and over; Alzheimer Disease; Antioxidants; Brain; Carica; Case-Control Studies; Deoxyguanosine; Dietary Supplements; Female; Fermentation; Humans; Lipid Peroxidation; Male; Oxidation-Reduction; Oxygen; Plant Preparations; Powders; Reactive Oxygen Species; Oxidative Stress; Immunology; Cell BiologyOxygenOxidative StressEndocrinologychemistryCase-Control StudiesDietary SupplementsFermentationPlant PreparationsLipid PeroxidationReactive Oxygen SpeciesOxidative stressdescription
Brain tissue is particularly susceptible to oxidative stress (OS). Increased production of reactive oxygen species (ROS), reduced antioxidant systems, and decreased efficiency in repairing mechanisms have been linked to Alzheimer’s disease (AD). Postmortem studies in AD patients’ brains have shown oxidative damage markers (i.e., lipid peroxidation, protein oxidative damage, and glycoxidation). Fermented papaya (FPP, a product ofCarica papaya Linnfermentation with yeast) is a nutraceutical supplement with favorable effects on immunological, hematological, inflammatory, and OS parameters in chronic/degenerative diseases. We studied 40 patients (age 78.2 ± 1.1 years), 28 AD patients, and 12 controls. Urinary 8-OHdG was measured to assess OS. Twenty AD patients were supplemented with FPP (Immunage, 4.5 grams/day) for 6 months, while controls did not receive any treatment. At baseline, 8-OHdG was significantly higher in patients with AD versus controls (13.7 ± 1.61 ng/mL versus 1.6 ± 0.12 ng/mL,P<0.01). In AD patients FPP significantly decreased 8-OHdG (14.1 ± 1.7 ng/mL to 8.45 ± 1.1 ng/mL,P<0.01), with no significant changes in controls. AD is associated with increased OS, and FPP may be helpful to counteract excessive ROS in AD patients.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-01-01 |